FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to therapy and cardiology, and concerns treating severe cardiovascular diseases. That is ensured by administering a combination of naltrexone and bupropion or their pharmaceutically acceptable salts.
EFFECT: it provides effective prevention of cardiovascular diseases and reduction of overweight in patients with point risk rating less than 0,8.
20 cl, 14 tbl, 11 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING PATIENTS WITH A HIGH RISK OF CARDIOVASCULAR DISEASES HAVING HYPERCHOLESTEROLEMIA | 2015 |
|
RU2723018C2 |
| METHODS OF TREATING PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) | 2015 |
|
RU2735521C2 |
| INCREASE IN BIOAVAILABILITY OF DRUGS IN THERAPY WITH NALTREXONE | 2011 |
|
RU2781141C2 |
| 1-METHYLNIKOTINAMIDE USE FOR TREATMENT OF DISEASES ASSOCIATED WITH C-REACTIVE PROTEIN | 2017 |
|
RU2744615C2 |
| INCREASE OF DRUG BIDOSTASTICITY AT THERAPY BY NALTREXONE | 2011 |
|
RU2640561C2 |
| METHODS FOR REDUCING BINGE OR COMPULSIVE EATING | 2011 |
|
RU2620913C2 |
| SEMAGLUTIDE IN CARDIOVASCULAR CONDITIONS | 2017 |
|
RU2768283C2 |
| TREATMENT OF MYOCARDIAL INFARCTION WITH REGENERATED HIGH-DENSITY LIPOPROTEIN | 2017 |
|
RU2798830C2 |
| METHOD OF TREATING OR PREVENTING ATHEROTHROMBOTIC EVENTS IN PATIENTS WITH MYOCARDIAL INFARCTION IN PAST HISTORY | 2016 |
|
RU2707959C2 |
| METHOD OF OBESITY TREATMENT | 2003 |
|
RU2341259C2 |
